- Home
- TWST
as 09-05-2025 3:20pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.3B | IPO Year: | 2018 |
| Target Price: | $50.67 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.28 - $55.33 | Next Earning Date: | 08-04-2025 |
| Revenue: | $362,273,000 | Revenue Growth: | 22.72% |
| Revenue Growth (this year): | 22.28% | Revenue Growth (next year): | 17.40% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Aug 25 '25 | Sell | $27.69 | 853 | $23,620.42 | 48,689 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Aug 21 '25 | Sell | $25.96 | 2,716 | $70,518.22 | 637,005 | |
| Green Paula | TWST | SVP of Human Resources | Aug 21 '25 | Sell | $25.96 | 619 | $16,071.72 | 125,729 | |
| Cho Dennis | TWST | See Remarks | Aug 21 '25 | Sell | $25.96 | 521 | $13,527.24 | 103,306 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Aug 21 '25 | Sell | $25.96 | 238 | $6,179.43 | 48,689 | |
| Finn Patrick John | TWST | President and COO | Aug 21 '25 | Sell | $25.96 | 1,840 | $47,773.76 | 233,529 | |
| Laponis Adam | TWST | Chief Financial Officer | Aug 21 '25 | Sell | $25.96 | 918 | $23,834.95 | 102,917 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Jun 20 '25 | Sell | $35.76 | 1,678 | $59,996.89 | 637,005 | |
| Green Paula | TWST | SVP of Human Resources | Jun 20 '25 | Sell | $35.76 | 292 | $10,440.46 | 125,729 | |
| Cho Dennis | TWST | See Remarks | Jun 20 '25 | Sell | $35.76 | 230 | $8,223.65 | 103,306 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Insider Monkey
2 months ago
Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions
Simply Wall St.
3 months ago
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
MT Newswires
3 months ago
Twist Bioscience Expands Element Biosciences Partnership for End-to-End NGS Tools
Business Wire
3 months ago
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Business Wire
4 months ago
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
Business Wire
4 months ago
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insider Monkey
4 months ago
Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential
MT Newswires
4 months ago
Twist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.